This New CRISPR Technique Flips Genes Back On Without Touching DNA

Introduction: when cutting is no longer the only option

Classic CRISPR and its Achilles' heel

Since its discovery, the CRISPR system has revolutionized biology by offering a relatively simple way to modify the genome. Its basic principle relies on molecular scissors: a protein guided by a fragment of RNA cuts DNA at a precise spot, allowing a genetic sequence to be disabled, corrected, or inserted afterward. This method has enabled major therapeutic advances, but it carries an inherent risk: every cut in the double helix can lead to repair errors, unwanted mutations, or even longer-term genomic instability.

It is precisely this Achilles' heel that a team of researchers from the University of New South Wales, working with St Jude Children's Research Hospital in Memphis, has just sidestepped with remarkable elegance. Published in January 2026 in the journal Nature Communications, their study demonstrates that it is possible to wake up silenced genes without ever cutting the DNA strand, by targeting an entirely different level of genetic regulation.

Chemical anchors instead of scissors

The key to this breakthrough lies in a mechanism called DNA methylation. Small chemical tags, called methyl groups, attach to certain portions of the genome and act as molecular anchors that keep genes locked in an "off" position. For decades, the scientific community debated the following question: are these chemical marks the direct cause of genetic silencing, or are they merely a sign accompanying genes that are already inactive for other reasons? Professor Merlin Crossley, lead author of the study and deputy vice-chancellor academic at UNSW, sums up the discovery with a vivid image: removing these marks is like "clearing away the cobwebs," and the gene switches back on immediately, as though an invisible brake had been released.

A scientific debate finally settled

Remove, then reapply: proof by experiment

To demonstrate that DNA methylation does not merely accompany genetic silencing but is in fact its direct cause, the team designed a two-stage experiment. First, researchers used a modified version of the CRISPR system, stripped of its cutting function, to deliver enzymes capable of removing the methyl groups from a target gene. The result: the silent gene resumed normal expression. Next, by adding the methyl marks back onto that same gene, the team observed its silencing return. This full reversibility, achieved in the lab on human cells, provides direct, not merely correlative, proof of methylation's causal role in gene silencing.

Professor Kate Quinlan, co-author of the study, notes that this epigenetic editing approach can boost a gene's expression without ever altering the DNA sequence itself. According to her, therapies built on this technology should carry a reduced risk of unwanted side effects compared with the first and second generations of CRISPR tools, both of which rely on cutting the double helix.

A tool called dCas, stripped of its scissors

Technically, the system used relies on a catalytically inactive version of the Cas9 protein, often called dCas9, which is unable to cut DNA. This protein acts purely as a delivery vehicle, guided by RNA to the precise location of the target gene, where it drops off an enzyme tasked with removing or adding methylation marks. This conceptual shift, from molecular scissors to a targeted delivery system, opens up an entirely new category of gene-editing tools, one that some researchers already describe as a third generation of genome editing.

Unlike first-generation tools, which disable genes by cutting them, and second-generation tools, which correct individual letters of the genetic code, this epigenetic approach never touches the structure of the DNA itself. It acts only on its accessibility, somewhat like flipping a switch rather than rewiring the electrical circuit itself at a deeper level.

A first concrete application: sickle cell disease

Waking a fetal gene in adults

The first application envisioned by the Australian team concerns sickle cell disease, a genetic blood disorder. Every human being carries a fetal globin gene, which functions perfectly before birth by producing a healthy form of hemoglobin, before being naturally switched off shortly afterward. In people with sickle cell disease, the adult hemoglobin their bodies produce is defective and causes red blood cells to become misshapen. The researchers' idea is to reactivate this dormant fetal gene, rather than attempting to directly repair the adult gene responsible for the disease.

The envisioned clinical scenario would work like this: draw a patient's blood stem cells, apply epigenetic editing in the lab to remove the methyl marks keeping the fetal globin gene switched off, then reinject these modified cells into the body. Once settled into the bone marrow, they could then produce healthier red blood cells, all without the patient's DNA sequence ever being cut or rewritten.

Promise beyond sickle cell disease alone

While sickle cell disease is the first target for this technology, its potential extends well beyond that single illness. Researchers point to possible applications for certain cancers, where the goal would be to reactivate tumor suppressor genes that have been silenced by methylation, or for developmental disorders such as fragile X syndrome, where a key gene is likewise switched off through this same epigenetic mechanism. The possibility of simply reversing a chemical mark, rather than rewriting an entire segment of the genome, opens up a considerable therapeutic field for many diseases that remain incurable today.

All these experiments remain, for now, confined to the laboratory, carried out on cultured human cells at UNSW and in Memphis. The next steps planned by the team include tests in animal models, before moving, if the results hold up, toward human clinical trials.

Why this approach changes the safety equation

The risk of DNA cuts finally sidestepped

Traditional CRISPR tools, whether fully disabling a gene or correcting a single mutation, almost always rely on creating a double-strand break in the DNA molecule. This process, while powerful, carries documented risks: imperfect repairs, unwanted insertions or deletions, chromosomal rearrangements, and in some cases disruptions that can favor the development of cancerous cells. These risks have always been a significant barrier to the large-scale use of gene therapies based on directly cutting DNA.

By avoiding these cuts entirely, the epigenetic editing proposed by the Crossley and Quinlan team mechanically reduces this type of complication. Since the genetic sequence remains physically intact from start to finish of the treatment, the risk of accidental long-term mutations drops significantly, which could make it easier for these future therapies to gain regulatory and clinical acceptance among both patients and health authorities.

A reversibility that changes the treatment philosophy

Another major advantage of this approach is its reversibility in principle. Because the modification relies on adding or removing chemical marks, rather than permanently rewriting the genetic code, it becomes theoretically possible to undo an intervention if necessary, by reapplying enzymes capable of restoring the original methylation. This feature fundamentally sets this technology apart from classic genetic edits, which are generally designed to be permanent and irreversible once applied to a patient.

This flexibility opens the door to a more adjustable form of genetic medicine, where a gene's expression could be fine-tuned as a patient's condition evolves, rather than fixed once and for all by a molecular-level surgical intervention.

Conclusion: a new generation of gene editing

What this discovery confirms

This study, led by UNSW Sydney and St Jude Children's Research Hospital, settles a long-standing scientific debate by demonstrating that DNA methylation directly causes the silencing of certain genes, rather than the other way around. More importantly, it proves that it is possible to act on this methylation with precision, using the CRISPR system not as scissors but as a targeted delivery tool for enzymes, without ever cutting the DNA molecule.

The potential therapeutic implications, starting with sickle cell disease, still need to be confirmed through trials in animal models and then in humans. But the very principle behind this method marks an important step in the evolution of gene-editing tools, opening up a more cautious and potentially safer path than previous approaches.

Still a long road to the clinic

It is worth remembering that all these results currently come exclusively from laboratory experiments on cultured human cells. The move to animal models, and then to clinical trials, will take time and will need to confirm that the effects observed in the lab hold up in a complete living organism, with all the physiological complexity that implies. Even so, this advance illustrates how fundamental research in biology keeps generating ever finer, safer tools for treating genetic diseases that have, until now, resisted classic therapeutic approaches.

This kind of progress also serves as a broader reminder of how science rarely advances through isolated, spectacular leaps. Most often it moves forward in small successive steps, with each research team building on the discoveries of those before it to refine a tool, resolve a technical detail, or lift a persistent uncertainty. Epigenetic editing is no exception to this rule: it builds on decades of research into DNA methylation and on the CRISPR tools themselves, before finally converging on this gentler, potentially safer approach for tomorrow's patients.

By Maxime Marquette, columnist

Columnist's transparency note

What this narrative relies on

This narrative account draws on the published Nature Communications study, university press communications from UNSW, and coverage from outlets specializing in genetics and biotechnology. I am not a molecular biologist, and I have kept the scientific claims tied closely to what the researchers themselves state in their publication and public statements.

I have deliberately avoided suggesting that any human treatment is imminent, since the researchers themselves describe this work as still confined to laboratory experiments on cultured cells.

Sources

Primary sources

ScienceDaily — This CRISPR breakthrough turns genes on without cutting DNA — January 2026

Nature Communications — Removal of promoter CpG methylation by epigenome editing reverses HBG silencing — 2025

UNSW Sydney — Research on epigenetic editing and the reactivation of silenced genes — January 2026

Secondary sources

Futura Sciences — Accessible analysis of advances in CRISPR epigenetic editing — 2026

Sciences et Avenir — Coverage of innovations in gene therapy and CRISPR — 2026

Amphi Sciences Ouest-France — Accessible coverage of research in molecular biology and genetics — 2026